For patients whose depression has not responded to standard antidepressant treatment, Spravato — FDA-approved
esketamine nasal spray — represents a clinically meaningful option. Ample Grace Psychiatry is actively building
toward offering Spravato at our Golden Valley office for adults with treatment-resistant depression.
Free to join · No commitment · Be first to know when we launch
Spravato is an FDA-approved nasal spray for treatment-resistant depression. It may be considered when major depressive disorder has not responded adequately to at least two antidepressants at therapeutic doses and durations.
Unlike traditional antidepressants, Spravato works through the glutamate system and NMDA receptors. It is administered in-office under clinical supervision, with patients monitored for approximately two hours after each treatment.
You may be a candidate when Spravato becomes available if:
For patients who have not found adequate relief from standard antidepressants, Spravato offers a different treatment option. At Ample Grace Psychiatry, we believe patients with difficult-to-treat depression deserve access to advanced treatment options close to home.
Free to join · No commitment · Be first to know when we launch
If you have struggled with depression despite trying multiple antidepressants — and you would like to be notified when
Spravato becomes available at Ample Grace Psychiatry — please complete the brief form below. We will contact you
directly when our program launches and discuss whether you may be a candidate.
Spravato is not yet available at Ample Grace Psychiatry. This page is for informational purposes and to capture patient interest
ahead of our planned program launch. Joining the interest list does not constitute a clinical evaluation or guarantee of treatment.
We work alongside therapists, primary care providers, OB-GYNs, and psychologists across Minnesota. If you’re a provider looking to refer a patient, we make the process simple.
Questions? Call 800-223-4914
